Abstracts tagged "Biomarkers"

Abstract Number: 0975 • ACR Convergence 2022
Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE
Paul Newcombe¹, Richard A. Furie², Yoshiya Tanaka³, Wendy White⁴, Dominic Sinibaldi⁴, Philip Brohawn⁴, Mark Lazarus¹, Nicola Ferrari¹, Raj Tummala⁴, Hussein Al-Mossawi¹, Andre Nogueria da Costa⁵, Daniel Muthas⁵ and Madhu Ramaswamy⁴, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴AstraZeneca, Gaithersburg, MD, ⁵AstraZeneca, Gothenburg, Sweden
Background/Purpose: SLE has been associated with expression of type I IFN gene signatures (IFNGS).1 Anifrolumab, a monoclonal antibody binding IFN receptor subunit 1, inhibits downstream…
Abstract Number: 1221 • ACR Convergence 2022
Multi-Center Validation of Cell-Bound Complement Activation Products and a Multianalyte Assay Panel Distinguishing Systemic Lupus Erythematosus from Primary Fibromyalgia
Mark Rudolph¹, Scott Rey¹, Alan Kivitz², Stuart Silverman³, Roland Staud⁴ and Roberta Alexander¹, ¹Exagen, Inc., Vista, CA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of Florida, Gainesville, FL
Background/Purpose: A 2016 article in Lupus Science & Medicine (Wallace et al. 2016) described the ability of cell-bound complement activation products (CB-CAPs) on their own--…
Abstract Number: 1487 • ACR Convergence 2022
Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
James Krueger¹, Kilian Eyerich², Dennis McGonagle³, Carrie Greving⁴, Kacey Sachen⁴, Deepa Hammaker⁴, Phuc Bao⁴, Eilyn Lacy⁴, M. Merle Elloso⁵, Yevgeniya Orlovsky⁵, Iain B McInnes⁶ and Anne Fourie⁷, ¹The Rockefeller University, New York, NY, ²Technical University, Munich, Germany / Karolinska Institute, Stockholm, Sweden, ³University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁴Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, ⁵Janssen Research and Development, LLC, Spring House, PA, ⁶Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁷Janssen Research & Development, LLC, San Diego, CA, USA, San Diego, CA
Background/Purpose: Clinically relevant differences between therapeutic antibodies against the same target may relate to their unique molecular attributes. Differences in therapeutic profiles across the domains…
Abstract Number: 1655 • ACR Convergence 2022
Belimumab Disrupts Memory B-Cell Trafficking in Patients with Systemic Lupus Erythematosus
Eline J. Arends¹, Mihaela Zlei², Christopher M. Tipton³, Jasna Cotic⁴, Zgjim Osmani¹, Fenna J. De Bie², Sylvia W.A. Kamerling¹, Andre Van Maurik⁵, Richard Dimelow⁶, Yun Irene Gregan⁷, Norma Lynn Fox⁸, Ton J. Rabelink¹, David A. Roth⁹, Iñaki Sanz¹⁰, Jacques J.M. Van Dongen², Cees Van Kooten¹ and Onno Teng¹¹, ¹Department of Nephrology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Immunology, Leiden University Medical Center, Leiden, Netherlands, ³Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA, ⁴Clinical Statistics, GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom, ⁶GlaxoSmithKline, Clinical Biomarker Group, Stevenage, United Kingdom, ⁷GlaxoSmithKline, Clinical Science Immunology, Collegeville, PA, ⁸GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA, ⁹GlaxoSmithKline, Research and Development, Collegeville, PA, ¹⁰Emory University, Atlanta, GA, ¹¹Leiden University Medical Center, Leiderdorp, Netherlands
Background/Purpose: Belimumab (BEL), a recombinant human monoclonal antibody directed against B-cell activating factor (BAFF), is the first approved biological agent for patients (pts) with active…
Abstract Number: 1898 • ACR Convergence 2022
Radiographic Osteoarthritis Progression Can Be Predicted via Pyrosequencing Analysis of Baseline Peripheral Blood
Chris Dunn¹, Cassandra Velasco², Leoni Schlupp³, Emmaline Prinz³, Vladislav Izda⁴, Liubov Arbeeva⁵, Yvonne Golightly⁶, Amanda Nelson⁶ and Matlock Jeffries³, ¹University of Oklahoma Health Sciences Center, Edmond, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, New York, NY, ⁵University of North Carolina Chapel Hill, Chapel Hill, NC, ⁶UNC School of Medicine, Chapel Hill, NC
Background/Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes. However, we do not yet have robust biomarkers…
Abstract Number: 2099 • ACR Convergence 2022
Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers
Ioannis Parodis¹, Julius Lindblom¹, Daniel Toro-Domínguez², Elena Carnero-Montoro², Maria Orietta Borghi³, Jessica Castillo⁴, Yvonne Enman⁵, Chandra Mohan⁴, Marta Alarcon-Riquelme² and Guillermo Barturen², ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, ⁴University of Houston, Houston, TX, ⁵Karolinska Institutet, Sundbyberg, Sweden
Background/Purpose: LN is one of the most severe organ manifestations of SLE and constitutes an important cause of morbidity and death among patients with SLE…
Abstract Number: 2252 • ACR Convergence 2022
Higher Matrix Metalloproteinase Levels Are Predictive of Incident Interstitial Lung Disease Among a Cohort of US Veterans with Rheumatoid Arthritis
Brent Luedders¹, Dana Ascherman², Joshua Baker³, Michael Duryee¹, Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, Paul Monach⁶, Andreas Reimold⁷, Gail Kerr⁸, Gary Kunkel⁹, Grant Cannon¹⁰, Jill Poole¹, Geoffrey Thiele¹, Ted Mikuls¹¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴UNMC, Omaha, NE, ⁵VA Puget Sound/University of Washington, Seattle, WA, ⁶VA Boston Healthcare System, Boston, MA, ⁷University of Texas Southwestern Medical Center, Dallas, TX, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT, ¹¹Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Matrix metalloproteinases (MMPs) degrade extracellular matrix and have been implicated to play a role in a number of fibrotic processes. Specifically, MMPs have been…
Abstract Number: 0029 • ACR Convergence 2022
Characterizing the Anti-fibrotic Effect of Tofacitinib in TGF-β Stimulated Fibroblast-like Synoviocytes from Patients with OA
Sofie Falkenløve Madsen¹, Sarah Madsen², Elle Hollaar³, Thorbjørn Gantzel⁴, Anne-Christine Bay-Jensen³ and Christian Thudium³, ¹University of Copenhagen / Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, University of Copenhagen, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Gentofte Hospital, Gentofte, Denmark
Background/Purpose: Many osteoarthritis (OA) patients develop fibrosis of the synovial membrane leading to joint swelling, stiffness, and pain. Synovial fibroblasts activated in the synovial membrane…
Abstract Number: 0310 • ACR Convergence 2022
Higher Baseline Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Predict Therapeutic Efficacy of Abatacept in Moderate to Severe Rheumatoid Arthritis
TING WANG, Natalia V. Giltiay, Christian Lood and Bobby Kwanghoon Han, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Activation of T cells plays a key role in the pathogenesis of rheumatoid arthritis (RA), which is characterized by inflammation of the synovial tissue…
Abstract Number: 0548 • ACR Convergence 2022
Postural Orthostatic Tachycardia Syndrome, Small Fiber Neuropathy, and Systemic Inflammation: Are They Related?
Elizabeth Bettini, Carolyn Ramwell, Sangeeta Sule and Jeffery Moak, Children's National Hospital, Washington, DC
Background/Purpose: Postural Orthostatic Tachycardia Syndrome (POTS) is a dysautonomia associated with chronic autonomic and neuropathic symptoms, including pain in multiple body regions, paresthesia, fatigue, brain…
Abstract Number: 0667 • ACR Convergence 2022
Correlation Matrices Visualize Differential Degree of Cell and Pathway Heterogeneity in Skin of Cutaneous Lupus Erythematosus Treatment Subgroups
Felix Chin¹, Thomas Vazquez², Josh Dan³, DeAnna Diaz⁴, Grant Sprow⁵, Jay Patel⁶, Nilesh Kodali⁷, Rui Feng⁸ and Victoria Werth⁹, ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Philadelphia College of Medicine, Philadelphia, PA, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, ⁷New Jersey Medical School, Coppell, TX, ⁸University of Pennsylvania, Philadelphia, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: First-line treatment for cutaneous lupus erythematosus involves the use of antimalarials. Treatment response is highly variable with some patients responding well to hydroxychloroquine (HCQ),…
Abstract Number: 0977 • ACR Convergence 2022
Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)
Jason S Knight¹, Winn Walter Chatham², Christine Henning³, Julia H N Harris⁴, Andre Van Maurik⁵, Roger A Levy⁶ and David Pisetsky⁷, ¹University of Michigan, Division of Rheumatology, Ann Arbor, MI, ²University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL, ³GlaxoSmithKline, Global Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom, ⁶GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁷Duke University Medical Center, Durham, NC
Background/Purpose: Serological and cellular biomarkers are used in clinical practice to guide the management of SLE. Increased levels of anti-dsDNA and decreased levels of complement…
Abstract Number: 1232 • ACR Convergence 2022
Reliability and Validity of Single Axial Slice vs. Multiple Slice Quantitative Measurement of the Volume of Effusion-Synovitis on 3T Knee MRI in Knees with Osteoarthritis
Greg Gilles¹, Arjun Vohra¹, Chelsea Caruso¹, Dagoberto Robles¹, Mihra Taljanovic¹, Jeffrey Duryea², Erin Ashbeck¹, Edward Bedrick³ and Kent Kwoh⁴, ¹University of Arizona Arthritis Center, Tucson, AZ, ²Brigham and Women's Hospital, Boston, MA, ³Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ⁴University of Arizona, Tucson, AZ
Background/Purpose: Effusion-synovitis (ES) on knee MRI has been identified as an important biomarker of OA. Semi-automated software methods offer objective measurements of ES volume on…
Abstract Number: 1500 • ACR Convergence 2022
Investigating Serum Lipids Classifying Psoriatic Arthritis Disease Activity Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry
John Koussiouris¹, Nikita Looby², Max Kotlyar³, Vathany Kulasingam⁴, Igor Jurisica⁵ and Vinod Chandran⁶, ¹Department of Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute/ Data Science Discovery Centre for Chronic Diseases, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto/ Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁵Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network/ Departments of Medical Biophysics and Computer Science, University of Toronto, Toronto, ON, Canada, ⁶Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Psoriasis is an inflammatory skin disease that affects over 7.25 million Americans and 1.25 million Canadians. Approximately 25% of psoriasis patients, have an inflammatory…
Abstract Number: 1685 • ACR Convergence 2022
The Presence of Anti-MAA Antibodies to Extracellular Matrix Proteins in Synovial Fluid and Sera of Patients with Rheumatoid Arthritis
Alexandra Taylor¹, Michael Duryee², Carlos Hunter², nozima Aripova², Ted Mikuls³ and Geoffrey Thiele², ¹Creighton University School of Medicine, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Antibodies to malondialdehyde-acetaldehyde protein adducts (MAA) are increased in both the serum and synovial joint fluid from patients with Rheumatoid Arthritis (RA). These antibodies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].